by John Conrad | Nov 5, 2024 | Policy News
Disclaimer: iBIO is a nonpartisan organization and does not endorse any candidate for public office. This article is provided for informational purposes only to help our members understand potential policy implications of election outcomes. As voters head to the polls...
by John Conrad | Oct 3, 2024 | Policy News
The Centers for Medicare & Medicaid Services (CMS) has announced significant changes to its drug price negotiation process for the Medicare program. These updates come in response to feedback from patients and pharmaceutical companies following the first round of...
by John Conrad | Sep 12, 2024 | Policy News
In a recent hearing, the Health Care Availability & Accessibility Committee delved into the complex world of Pharmacy Benefit Managers (PBMs) and specialty pharmacies, exposing a web of concerns affecting patient care and drug pricing. The hearing, which brought...
by John Conrad | Sep 10, 2024 | iBIO News, Policy News
iBIO has joined forces with fellow members of the Council of State Bioscience Associations (CSBA) in a crucial initiative to safeguard the future of rare pediatric disease research and treatment. Yesterday, our coalition sent a letter to congressional leaders, urging...
by John Conrad | Aug 15, 2024 | Policy News
Endpoints News reported that the Biden administration has unveiled projections for the Inflation Reduction Act’s (IRA) impact on drug pricing. According to the announcement, IRA negotiations are anticipated to generate $6 billion in taxpayer savings by 2026,...
by John Conrad | Aug 14, 2024 | Policy News
In a bold move to secure Illinois’ economic future, Governor JB Pritzker has unveiled a comprehensive five-year economic growth plan that places a strong emphasis on the life sciences sector. This strategic focus aims to position Illinois at the forefront of...